|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 900 7th Street, NW |
Address2 | Suite 975 |
City | Washington |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Mansfield |
State | MA |
Zip Code | 02048 |
Country | USA |
|
5. Senate ID# 319778-12
|
||||||||
|
6. House ID# 395090000
|
TYPE OF REPORT | 8. Year | 2012 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Timothy J. McBride VP Global Government Affairs |
Date | 10/19/2012 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
General issues related to FDA device approval process; issues related to Patient Protection and Affordable Care Act Implementation (Accountable Care Organization, Medical Device Tax); S.17/S.262/H.R.436/H.R.488/H.R.734: Medical Device Access and Innovation Protection Act (all provisions); HEU/LEU related issues for Nuclear Medicine. S.99: American Medical Isotopes Production Act (all provisions).
H.R. 3209: Premarket Predictability Act (All provisions related to the FDA and the regulation of medical devices generally);
H.R. 3203: Novel Device Regulatory Relief Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3230: Keeping America Competitive Through Harmonization Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3205: FDA Renewing Efficiency from Outside Review Management Act. (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3211: Humanitarian Device Reform Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3208: Patients Come First Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3206: Cultivating Scientific Experts to Foster Innovation Act (All provisions related to the FDA and the regulation of medical devices generally); H.R. 3214: Food and Drug Administration Mission Reform Act (All provisions related to the FDA and the regulation of medical devices generally);
H.R. 3204: Guidance Accountability and Transparency Act (All provisions related to the FDA and the regulation of medical devices generally); S. 1700: The Medical Device Regulatory Improvement Act (All provisions related to the FDA and the regulation of medical devices generally); S. 1865: The Patient Access to Medical Innovation Act (All provisions related to the FDA and the regulation of medical devices generally); S. 1943: Novel Device Regulatory Relief Act of 2011(All provisions related to the FDA and the regulation of medical devices generally); S. 1972: A bill to amend the Food and Drug Administrations mission (All provisions related to the FDA and the regulation of medical devices generally); S. 1995: A bill to enhance Food and Drug Administration oversight of medical device recalls, to provide for the conditional clearance of certain medical devices, and for other purposes (All provisions related to the FDA and the regulation of medical devices generally); S.3187: Food and Drug Administration Safety and Innovation Act as well as Amendment 2151 on reclassification of hydrocodone sponsored by Senator Manchin; Coverage issues for Transcutaneous Electronic Stimulation for chronic lower back pain.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Whitney |
Gardiner |
|
|
|
Jack |
Kalavritinos |
|
|
|
Timothy |
McBride |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
International tax on foreign direct investment generally; Corporate Tax Reform generally; S.1346: Stop Tax Haven Abuse Act (all provisions); H.R. 62: International Tax Competitiveness Act of 2011 (all provisions).
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Whitney |
Gardiner |
|
|
|
Timothy |
McBride |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
S.23/H.R.1249: America Invents Act (all provisions).
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Whitney |
Gardiner |
|
|
|
Jack |
Kalavritinos |
|
|
|
Timothy |
McBride |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Issues involving controlled substance and pain and addiction drugs generally; H.R. 2119: Ryan Creedon Act of 2011To amend the Controlled Substances Act to require practitioners to obtain particular training or special certification, approved by the Attorney General, on addiction to and abuse of controlled substances and appropriate and safe use of controlled substances in schedule II, III, IV, or V, and for other purposes; Issues related to acetaminophen.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Whitney |
Gardiner |
|
|
|
Jack |
Kalavritinos |
|
|
|
Timothy |
McBride |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Free Trade Agreement; HR 3078: United State Columbia Trade Promotion Agreement (All provisions relevant to medical device companies, in particular the device-specific provisions listed in the US-Korea Free Trade Agreement); HR 3079: United States Panama Trade Promotion Agreement (All provisions relevant to medical device companies, in particular the device-specific provisions listed in the US-Korea Free Trade Agreement)
HR 3080: United States - Korea Free Trade Agreement (All provisions relevant to medical device companies, in particular the device-specific provisions listed in the US-Korea Free Trade Agreement)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Whitney |
Gardiner |
|
|
|
Timothy |
McBride |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |